Transcatheter mitral valve-in-valve: treatment of rheumatic heart disease in young patients
- PMID: 36200709
- DOI: 10.1111/ans.18076
Transcatheter mitral valve-in-valve: treatment of rheumatic heart disease in young patients
Abstract
Background: Rheumatic heart disease (RHD) in young people presents a complex management problem. In Australia a significant proportion of those affected are Aboriginal and Torres Strait Islanders. Transcatheter mitral valve-in-valve (TMViV) replacement has emerged as an alternative to redo surgery in high-risk patients with degenerated mitral bioprostheses. The aim of this study is to review outcomes of TMViV replacement in young patients with RHD.
Methods: A single-centre, retrospective review of prospectively collected data on patients undergoing TMViV from December 2017 to June 2021. Primary outcome was major adverse cardiovascular events. Secondary outcome was post-operative trans-thoracic echocardiogram (TTE) results.
Results: There were seven patients with a mean age of 33 years and predominantly female (n = 5). Pre-operative comorbidities included diabetes (29%), chronic obstructive pulmonary disease (43%), left ventricular dysfunction (43%) and current smoking status (80%). Post-operative median length of hospital stay was 4 days with no post-operative renal failure, stroke, return to theatre, valve embolization or in hospital mortality. Post-operative TTE showed either nil or trivial central mitral regurgitation, no paravalvular leak and a median gradient of 5 mmHg (IQR 4.5, 7) across the new bioprosthesis; sustained at median follow-up of 22 months.
Conclusion: Current literature of TMViV replacement is focused on an older population with concurrent comorbidities. This study provides a unique insight into TMViV replacement in a young cohort of patients with complex social and geographical factors which sometimes prohibits the use of a mechanical valve. The prevalence of RHD remains high for Aboriginal and Torres Strait Islanders, planning for future repeat valve operations should be considered from the outset. We consider TMViV as a part of a staged procedural journey for young patients with RHD.
Keywords: aboriginal and Torres Strait Islander; degenerated bioprosthesis; rheumatic heart disease; transcatheter mitral valve-in-valve.
© 2022 Royal Australasian College of Surgeons.
References
-
- Hu J, Chen Y, Cheng S et al. Transcatheter mitral valve implantation for degenerated mitral bioprostheses or failed surgical annuloplasty rings: a systematic review and meta-analysis. J. Card. Surg. 2018; 33: 508-19.
-
- Sengupta A, Yazdchi F, Alexis SL et al. Reoperative mitral surgery versus Transcatheter mitral valve replacement: a systematic review. J. Am. Heart Assoc. 2021; 10: 1-13.
-
- Bourguignon T, Bouquiaux-Stablo AL, Loardi C et al. Very late outcomes for mitral valve replacement with the Carpentier-Edwards pericardial bioprosthesis: 25-year follow-up of 450 implantations. J. Thorac. Cardiovasc. Surg. 2014; 148: 2004-11.
-
- Foster A, Greenberg A, Underhill D, McIntosh C, Clark R. Intrinsic failure of Hancock mitral bioprostheses: 10- to 15-year experience. Ann. Thorac. Surg. 1987; 44: 568-77.
-
- Keenan NM, Newland RF, Baker RA, Rice GD, Bennetts JS. Outcomes of redo valve surgery in indigenous Australians. Heart Lung Circ. 2019; 28: 1102-11.
MeSH terms
LinkOut - more resources
Full Text Sources
